Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
BTAI Stock Chart & Stats
$2.25
-$0.09(-19.80%)
At close: 4:00 PM EST
$2.25
-$0.09(-19.80%)
Day’s Range― - ―
52-Week Range$1.17 - $9.62
Previous CloseN/A
Volume1.10M
Average Volume (3M)1.58M
Market Cap
$36.54M
Enterprise Value$104.56M
Total Cash (Recent Filing)$37.32M
Total Debt (Recent Filing)$109.29M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Mar 05, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding19,646,801
10 Day Avg. Volume1,230,633
30 Day Avg. Volume1,584,008
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)6.69
P/FCF Ratio-0.21
Enterprise Value/Market Cap2.86
Enterprise Value/Revenue139.04
Enterprise Value/Gross Profit-364.33
Enterprise Value/Ebitda-2.04
Forecast
1Y Price Target
$10.67Price Target Upside374.22% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessComplete resolution of agitation symptoms was significantly higher with BXCL501 compared to placebo across all severity levels of agitation episodes.
Market PotentialSafety data could pave the way for at-home use of BXCL501, which presents a significant opportunity as the need for safe and efficacious acute treatments for agitation remains very high.
Regulatory ApprovalThe favorable data from the SERENITY At-Home trial should be sufficient to warrant label extension.
Bears Say
Efficacy ConcernsMore questions than answers on efficacy releases.
Market Penetration ChallengesSignificant investment needed to effectively penetrate this population with work needed to improve physician and patient education on the potential value in the at-home setting.
Market ReactionThe stock, which had seen significant strength into the dataset, has been weak after the news.
Bioxcel Therapeutics News
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.17 and its highest was $9.62 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $36.54M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Mar 05, 2026 which is in 93 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$2.18 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.84.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -0.84.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 19,646,801 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$2.18 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -15.347%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Currently, no hedge funds are holding shares in BTAI
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.67 (374.22% Upside)
$10.67 (374.22% Upside)
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.59%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BTAI Stock 12 Month Forecast
Average Price Target
$10.67
▲(374.22% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Kezar Life Sciences
―
Annovis Bio
―
BioAtla
―
Century Therapeutics
―
Ownership Overview
2.95% Insiders
1.52% Mutual Funds
1.61% Other Institutional Investors
93.29% Public Companies and Individual Investors